In summary, as our understanding of MYC biology has increased and immunotherapeutic strategies, such as immune checkpoint blockade, have demonstrated clinical efficacy in treating hematologic malignancies, we have positive hopes for the future. The gene discussed is MYC; the disease is hematologic disorder.